Literature DB >> 9140815

Role of thyroid hormone and insulin in control of cardiac isomyosin expression.

F Haddad1, M Masatsugu, P W Bodell, A Qin, S A McCue, K M Baldwin.   

Abstract

Previous studies show that both diabetes and thyroid state exert a strong regulatory influence on the pattern of rodent cardiac isomyosin expression. Therefore, we determined the separate and combined effects of thyroid hormone (T3) and insulin treatment on rodent cardiac myosin heavy chain (MHC) expression using a model of combined thyroid deficiency (Tx) and diabetes (D). The combination of Tx and D completely transformed cardiac isomyosin expression such that the fast alpha-myosin heavy chain (MHC) was completely repressed at both the protein and mRNA level of expression; whereas, the slow beta-MHC was upregulated to constitute 100% of the total MHC pool, based on both protein and mRNA analyses. Daily low doses of exogenous T3 treatment (3 micrograms/kg b.w. i.p.). in the absence of insulin treatment, partially restored expression of the alpha-MHC, while inhibiting expression of the beta-isoform. In contrast daily insulin treatment (4 U/rat), in the absence of exogenous T3 treatment, failed to exert any significant influence on the pattern of isomyosin expression in the thyroid-deficient diabetic rat model. Furthermore, when exogenous T3 was administered in conjunction with insulin, the effect on MHC mRNA expression was greater than that of T3 alone, thus suggesting the existence of interaction between T3 and insulin action in the regulation of MHC mRNA expression. Collectively, these findings suggest that: (a) thyroid state is a dominant regulator of cardiac isomyosin phenotype: and (b) insulin does not exert any regulatory influence on cardiac MHC expression in a severe thyroid deficient state, instead it requires a critical level of circulating T3 in order to be effective in blunting MHC transformation associated with diabetes. It is thus concluded that the regulation of cardiac MHC by insulin is a complex mechanism involving interaction of insulin with subcellular factors likely to have impact on the specific action of T3. This interaction is disrupted in the absence of sufficient thyroid hormone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140815     DOI: 10.1006/jmcc.1996.0299

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  6 in total

1.  Role of myosin heavy chain composition in the stretch activation response of rat myocardium.

Authors:  Julian E Stelzer; Stacey L Brickson; Matthew R Locher; Richard L Moss
Journal:  J Physiol       Date:  2006-11-30       Impact factor: 5.182

2.  Low-dose T₃ replacement restores depressed cardiac T₃ levels, preserves coronary microvasculature and attenuates cardiac dysfunction in experimental diabetes mellitus.

Authors:  Nathan Y Weltman; Kaie Ojamaa; Evelyn H Schlenker; Yue-Feng Chen; Riccardo Zucchi; Alessandro Saba; Daria Colligiani; Viswanathan Rajagopalan; Christine J Pol; A Martin Gerdes
Journal:  Mol Med       Date:  2014-05-01       Impact factor: 6.354

3.  Gonadectomy alters myosin heavy chain composition in isolated cardiac myocytes.

Authors:  Kish L Golden; James D Marsh; Yang Jiang; Jerome Moulden
Journal:  Endocrine       Date:  2004-07       Impact factor: 3.633

4.  Determination of rate constants for turnover of myosin isoforms in rat myocardium: implications for in vivo contractile kinetics.

Authors:  Matthew R Locher; Maria V Razumova; Julian E Stelzer; Holly S Norman; Jitandrakumar R Patel; Richard L Moss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-24       Impact factor: 4.733

5.  Role of myosin heavy chain composition in kinetics of force development and relaxation in rat myocardium.

Authors:  D P Fitzsimons; J R Patel; R L Moss
Journal:  J Physiol       Date:  1998-11-15       Impact factor: 5.182

6.  Potential pitfalls in the accuracy of analysis of natural sense-antisense RNA pairs by reverse transcription-PCR.

Authors:  Fadia Haddad; Anqi X Qin; Julie M Giger; Hongyan Guo; Kenneth M Baldwin
Journal:  BMC Biotechnol       Date:  2007-05-04       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.